The Trial No Drug Company Would Fund

In 2015, a Finnish research team ran a 2-year trial on 1,260 older adults at elevated dementia risk. No drug. No patent. No pharmaceutical sponsor. Just diet, exercise, cognitive training, social activity, and vascular monitoring — five ordinary levers, pulled together instead of one at a time. The result: 25% greater improvement in cognition than standard advice, with executive function up 83% and processing speed up 150%. Eleven years later, the benefit was still measurable in the people who stuck with it. No single-target pill in dementia research has ever matched that combination of size, duration, and replication — and the honest reason is structural: nobody profitable was ever going to run this trial. It doesn't produce a molecule anyone can own.

Five levers, pulled at once

The trial is called FINGER — the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (Ngandu et al., The Lancet, 2015). It recruited people already flagged as at-risk (a CAIDE dementia risk score of 6 or higher) and split them into a control group getting standard health advice, and an intervention group getting five things at once: dietary counseling, a structured exercise program, cognitive training, social activities, and active management of vascular and metabolic risk factors. Nothing in that list is exotic. What's unusual is that almost nobody tests them together — pharmaceutical trials isolate a single mechanism because that's what a patent requires, and most lifestyle research tests one variable (just diet, just exercise) because that's what's fundable and publishable on its own. FINGER's entire premise was terrain, not target: stack the levers and see if the whole exceeds the sum of the parts. It did — improvement held across age, sex, education, and vascular profile, and APOE ε4 carriers, the group with the strongest genetic risk and the least pharmaceutical hope, benefited if anything more than average.

"Cognitive performance improved among participants in both groups, but the total average improvement of the intervention group was 25% greater than the improvement of the control group." Ngandu T, et al. "A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial." The Lancet, 2015.

It wasn't a fluke — it kept happening

A single positive trial proves less than people want it to. FINGER's strength is what came after it. An 11-year follow-up, published in Alzheimer's & Dementia in late 2025, found that lifestyle gains held significant through year 7, and that participants who stayed highly engaged throughout kept a measurable cognitive advantage over low-engagement peers all the way to year 11. That's not a 2-year sugar high — it's evidence the changes became durable habit, not a temporary trial effect. Then the model got tested outside Finland entirely. US POINTER, published in JAMA in July 2025, ran the same multidomain approach on 2,111 Americans — a larger, more diverse population than the original — and found that a structured, coached version of the program (38 facilitated group sessions over 2 years) outperformed a self-guided version of the identical components (6 sessions). That single comparison answers a question FINGER alone couldn't: the coaching and structure aren't decoration, they're the active ingredient that makes people actually do the five things consistently enough to matter. LatAm-FINGERS, reported in 2026 across eleven Latin American countries, found the same structured-beats-self-guided pattern again, in a third, culturally distinct population.

What honesty requires here: not every multidomain trial worked

Two comparable trials are worth naming precisely because they complicate the story. MAPT, the French multidomain Alzheimer prevention trial (3 years, 1,680 participants), missed its primary cognitive endpoint outright — it only showed benefit in a subgroup with high baseline risk or existing brain amyloid pathology. PreDIVA, a 6-year Dutch trial of nurse-led vascular risk management (3,526 participants), found no overall difference in dementia incidence, though an exploratory analysis found benefit specifically in people with previously untreated hypertension who then got treated. Neither failure erases FINGER — if anything, the pattern across all four trials sharpens the finding: intensity, coaching, and targeting people already at elevated risk seem to be the variables that separate a trial that works from one that doesn't. A vague, unsupervised "eat better and move more" doesn't reproduce FINGER's effect. The structure is doing real work, not just the ingredient list.

Why this belongs in the Neural Terrain Protocol

Every clearance and repair compound in the rest of the Neural Terrain Protocol — liposomal curcumin, carnosine, EGCG, erinacine-standardized Lion's Mane — still needs a functioning delivery and drainage system to reach neural tissue at all. That's the gap FINGER fills, and it's why Step 7 of the protocol, added specifically on this evidence, isn't graded by blood-brain-barrier penetration the way the botanical steps are. Exercise and blood pressure don't need to cross the barrier to matter — they act on the vasculature and cerebrospinal fluid dynamics that move everything else in and out.

Two findings tie directly into mechanisms this site has already covered. First: aerobic exercise is a documented glymphatic pump, not a generic wellness tip. A 2025 Nature Communications imaging study measured increased putative glymphatic influx and meningeal lymphatic vessel flow after 12 weeks of structured cycling — the exact waste-clearance system that only activates during deep sleep, the mechanism Step 1 of this protocol is built around. A separate randomized, controlled cross-over trial in seventeen sedentary men aged 60–70 found an 8-week supervised aerobic program increased cerebral blood flow by 27% in the frontal lobe, with a matched improvement in executive function (Kleinloog et al., Frontiers in Aging Neuroscience, 2019). Second: blood pressure is the single most concretely actionable vascular lever tested at scale. SPRINT MIND, a trial of 9,361 adults, found intensive systolic control (target <120mmHg) reduced the risk of mild cognitive impairment by 19% and the combined risk of MCI or probable dementia by 15%, compared to standard control (<140mmHg) — worth stating precisely: the effect on dementia alone didn't reach statistical significance, partly because the trial was stopped early for cardiovascular reasons before dementia cases could fully accumulate (Williamson et al., JAMA, 2019). That's a real, honest limit on the claim, not a reason to discard it.

What about diet?

It was one of FINGER's five original levers, and it isn't in the Neural Terrain Protocol's Step 7 above — worth explaining directly rather than leaving as a silent gap. FINGER's dietary counseling followed Finnish national nutrition guidelines: more vegetables, fruit, whole grains, fish, and unsaturated fat, less saturated fat and added sugar — in practice close to a Nordic/Mediterranean pattern. That overlaps heavily with the MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay), which has its own separate observational evidence base for slower cognitive decline. The reason it's absent from Step 7 specifically is a deliberate editorial line, not a claim that diet doesn't matter: exercise and blood pressure have a documented direct mechanistic tie to this protocol's own machinery — the glymphatic pump, cerebral blood flow — while diet's benefit here looks more systemic, working through the same vascular and metabolic risk factors that the blood-pressure half of this step already targets, rather than through a separate mechanism of its own. That's a judgment call about where to draw the step boundary, not evidence that the dietary arm of FINGER did less work. If you're running this protocol, treat Nordic/Mediterranean-style eating as the assumed floor underneath Step 7, not as something optional you can skip because it isn't its own numbered line.

This step is graded honestly on where the evidence is still thin: the exercise-glymphatic link is new (2025) and still measured through imaging proxies — "putative" flow, not direct human waste-clearance measurement, which remains animal-model territory. That's a smaller gap than most of this protocol's botanical steps carry, not a bigger one. FINGER, US POINTER, and LatAm-FINGERS are large human randomized controlled trials — the strongest evidence tier in the entire protocol, stronger than any single herb on this site.

The full protocol — sleep architecture, BBB-permeable clearance compounds, the vagal bypass route, and this vascular layer — is laid out step by step on the Neural Terrain Protocol page.

Sources

1. Ngandu T, Lehtisalo J, Solomon A, et al. "A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial." The Lancet 2015;385:2255-2263. PMID 25771249.
2. Ngandu T, et al. 11-year long-term follow-up of the FINGER trial. Alzheimer's & Dementia 2025. PMCID PMC12726459.
3. Rosenberg A, Mangialasche F, Ngandu T, Solomon A, Kivipelto M. "Multidomain Interventions to Prevent Cognitive Impairment, Alzheimer's Disease, and Dementia: From FINGER to World-Wide FINGERS." J Prev Alzheimers Dis 2019;7(1):29-36. PMID 32010923.
4. Baker LD, Espeland MA, Whitmer RA, et al. "Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial." JAMA 2025.
5. Kleinloog JPD, Mensink RP, Ivanov D, et al. "Aerobic Exercise Training Improves Cerebral Blood Flow and Executive Function: A Randomized, Controlled Cross-Over Trial in Sedentary Older Men." Frontiers in Aging Neuroscience 2019;11:333. PMID 31866855.
6. Williamson JD, Pajewski NM, Auchus AP, et al. "Effect of Intensive vs Standard Blood Pressure Control on Probability of Dementia: A Randomized Clinical Trial (SPRINT MIND)." JAMA 2019;321:553-561.
7. "Long-term physical exercise facilitates putative glymphatic and meningeal lymphatic vessel flow in humans." Nature Communications 2025.
8. LatAm-FINGERS results, presented 2026 — 11-country Latin American multidomain lifestyle trial. Cited as reported; primary publication not yet independently verified against the full text at time of writing.